m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01338)
Name
C-178
Synonyms
329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide
    Click to Show/Hide
Status
Investigative
Structure
Formula
C17H10N2O5
InChI
1S/C17H10N2O5/c20-17(14-7-8-16(24-14)19(21)22)18-10-5-6-12-11-3-1-2-4-13(11)23-15(12)9-10/h1-9H,(H,18,20)
InChIKey
URUVDCCYSJEGQQ-UHFFFAOYSA-N
PubChem CID
2866412
TTD Drug ID
D7CI5F
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Stimulator of interferon genes protein (TMEM173)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Stimulator of interferon genes protein (TMEM173) is a therapeutic target for C-178. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of C-178 through regulating the expression of Stimulator of interferon genes protein (TMEM173). [1], [2]
References
Ref 1 ALKBH5-Modified HMGB1-STING Activation Contributes to Radiation Induced Liver Disease via Innate Immune Response. Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):491-501. doi: 10.1016/j.ijrobp.2021.05.115. Epub 2021 May 24.
Ref 2 Clinical pipeline report, company report or official report of F-star Therapeutics.